Cancer Biosimilars Market Size, Share & Trends Analysis Report By Type (Lung Cancer, Breast cancer, Ovarian cancer, Prostate cancer, Lymphoma, Others), By Distribution Channel, By Drug Class, By Route of Administration, Region And Segment Forecasts, 2023-2031
The Cancer Biosimilars Market is expected to grow at a 20.0 % CAGR during the forecast period for 2023-2031.
Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. This is relatively cheaper than biologics. The abnormal growth of call is called cancer. Cancer is the second leading cause of death across the globe. Many biologic therapies are currently approved for the treatment of cancer, but due to high cost, it is not affordable in low-income countries. Growing demand for biosimilar and increase in demand for cost-effective treatment in low and medium-income countries drives the growth of the market during the forecast period.
Certain anti-cancer drugs had lost patents along with many drugs are going to lose the patent in coming years; thus, cancer biosimilars are expected to gain popularity in the coming year. A growing number of cancer patients and entry of biosimilars into the market, rising number of mergers and acquisitions by key players to grab the market share further drives the growth of the global cancer biosimilar market. However, complicated manufacturing process and stringent regulatory hurdles for the approval of biosimilars are the factors restrains the growth of the market.
Market Segmentation
The global cancer biosimilar market is segmented on the basis of Biologic class, Type, Drug Class, Route of Administration, Distribution Channel, and Region. The Bilogic class segment comprises Bevacizumab, Rituximab, Trastuzumab, Filgrastim, Pegfilgrastim, Denosumab, and others (including products approved in developing countries and pipeline products). On the basis of type, the global cancer biosimilar market is segmented into lung cancer, breast cancer, ovarian cancer, prostate cancer, lymphoma, and many more. An increase in the number of cancer patients and approval of biosimilars has boosted the growth of the market. Based on distribution channels, the global biosimilar market is further sub-segmented into online pharmacy, hospital pharmacy, and retail pharmacy. Hospital pharmacy is a major contributor in terms of revenue to the market due to the increase in the number of hospital visits and hospital stays; however, online pharmacy is witnessed to grow at a higher pace in the forecast period due to an increase in the number of internet users and ease of use. Drug Class Segment consists of G-CSF, Monoclonal Antibody, and Hematopoietic Agents. While Rout of adminstration includes Intravenous, Subcutaneous, and Others.
At the regional level, the global cancer biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of revenue, North America is expected to be the dominant global market over the forecast period. The first biosimilar approved by the U.S. FDA is in 2015, which is almost ten years later than Europe. However, since 2015, the U.S has approved many biosimilar, for instance, as of 2017, FDA approved five biosimilars, out of which two are approved for cancer.
Furthermore, robust clinical pipeline and increasing research and drug development activities propel the growth of the market in North America. Europe is a major contributor to the global cancer biosimilar market. This is partly because of increased government initiatives for cost-effective treatment and an increase in demand for biosimilars. The Asia Pacific is the third promising revenue contributor, which is expected to grow at a rapid pace in the upcoming year. Countries such as Japan, India, and China are major contributors for this market and are identified as most lucrative for this market. Emerging and huge population base countries such as China and India offers tremendous market opportunities. Furthermore, low cost biosimilars perfectly suffice to the budgets of the people in this region.
Competitive Landscape
Some of The Key Players in the Cancer Biosimilars Market:
- Mylan
- Amgen
- Pfizer
- Celltrion
- Samsung Bioepis
- Bio-Thera Solutions
- Sandoz (Novartis)
- Teva
- Coherus BioSciences
- CuraTeQ Biologics
- Accord Healthcare
- Allergan
- Biocon
- Merck
- Accord BioPharma
- Accord Healthcare S.L.U.
- AffaMed
- Biosimilar Collaborations Ireland Limited
- Reddy’s
- Henlius
- Intas
- Mabxience
- Nippon Kayaku
- Sandoz GmbH
- Amgen Inc.
- Amneal Pharmaceuticals, Inc.
- Betta Pharmaceuticals/Beijing Mabworks
- Bio-Thera Solutions, Ltd.
- Celltrion, Inc.
- Cipla
- Reddy’s Laboratories
- FGK Representative Service GmbH
- Hetero
- Innovent Biologics
- mAbxience Holding, S.L.
- Outlook Therapeutics Limited
- Pfizer Inc.
- Roche Registration GmbH
- Samsung Bioepis NL B.V.
- Sandoz Inc.
- Shanghai Henlius Biotech
- STADA Arzneimittel AG
- TOT BIOPHARM
- AstraZeneca PLC
- Samsung Bioepis Co., Ltd.
- Organon & Co.
- Other prominent players
The Cancer Biosimilars Market Report Scope
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 20.0 % from 2023 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Biologic Class, By Type, By Distribution Channel, By Drug Class, By Route of Administration |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Mylan, Amgen, Pfizer, Celltrion, Samsung Bioepis, Bio-Thera Solutions, Sandoz (Novartis), Teva, Coherus BioSciences, CuraTeQ Biologics, Accord Healthcare, Allergan, Biocon, Merck, Accord BioPharma, Accord Healthcare S.L.U., AffaMed, Biosimilar Collaborations Ireland Limited, Dr. Reddy’s, Henlius, Intas, Mabxience, Nippon Kayaku, Sandoz GmbH, Amgen Inc., Amneal Pharmaceuticals, Inc., Betta Pharmaceuticals/Beijing Mabworks, Bio-Thera Solutions, Ltd., Celltrion, Inc., Cipla, Dr. Reddy’s Laboratories, FGK Representative Service GmbH, Hetero, Innovent Biologics, mAbxience Holding, S.L., Outlook Therapeutics Limited, Pfizer Inc., Roche Registration GmbH, Samsung Bioepis NL B.V., Sandoz Inc., Shanghai Henlius Biotech, STADA Arzneimittel AG, TOT BIOPHARM, AstraZeneca PLC, Samsung Bioepis Co., Ltd., Organon & Co., and other prominent players. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Cancer Biosimilars Market Segmentation
Global Cancer Biosimilars Market Outlook By Biologic class
- Bevacizumab
- Rituximab
- Trastuzumab
- Filgrastim
- Pegfilgrastim
- Denosumab
- Others (Products approved in developing countries & pipeline products)
Global Cancer Biosimilars Market Outlook By Type
- Lung Cancer
- Breast cancer
- Ovarian cancer
- Prostate cancer
- Lymphoma
- Others
Global Cancer Biosimilars Market Outlook By Drug Class
- G-CSF
- Monoclonal Antibody
Global Cancer Biosimilars Market Outlook By Route Of Administration
- Intravenous
- Subcutaneous
- Others
Global Cancer Biosimilars Market Outlook By Distribution channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Cancer Biosimilar Market Outlook By Region
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- North America
- U.S.
- Canada
- Asia Pacific
- India
- China
- Japan
- South Korea
- Australia & New Zealand
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
The Cancer Biosimilars Market is expected to grow at a 20.0 % CAGR during the forecast period for 2023-2031.
Mylan, Amgen, Pfizer, Celltrion, Samsung Bioepis, Bio-Thera Solutions, Sandoz (Novartis), Teva, Coherus BioSciences, CuraTeQ Biologics, Accord Healthc
Biologic Class, Type, Distribution Channel, Drug Class, and Route of Administration are the key segments of the Cancer Biosimilars Market.
North American region is leading the Cancer Biosimilars Market.